Literature DB >> 29936551

Current and Emerging Therapies for Duchenne Muscular Dystrophy.

Megan Crone1,2, Jean K Mah3.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize the current and emerging therapies for Duchenne muscular dystrophy (DMD). RECENT
FINDINGS: Coinciding with new standardized care guidelines, there are a growing number of therapeutic options to treat males with DMD. Treatment of the underlying pathobiology, such as micro-dystrophin gene replacement, exon skipping, stop codon read-through agents, and utrophin modulators showed variable success in animal and human studies. Symptomatic therapies to target muscle ischemia, enhance muscle regeneration, prevent muscle fibrosis, inhibit myostatin, and reduce inflammation are also under investigation. DMD is a complex, heterogeneous degenerative disease. The pharmacological and technological achievements made in recent years, plus timely supportive interventions will likely lead to an improved quality of life for many individuals with DMD.

Entities:  

Keywords:  Disease-modifying treatments; Duchenne muscular dystrophy; Review

Year:  2018        PMID: 29936551     DOI: 10.1007/s11940-018-0513-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  111 in total

1.  The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article.

Authors:  David J Birnkrant; Katharine M D Bushby; Raouf S Amin; John R Bach; Joshua O Benditt; Michelle Eagle; Jonathan D Finder; Maninder S Kalra; John T Kissel; Anastassios C Koumbourlis; Richard M Kravitz
Journal:  Pediatr Pulmonol       Date:  2010-08

Review 2.  Dystrophin, its interactions with other proteins, and implications for muscular dystrophy.

Authors:  James M Ervasti
Journal:  Biochim Biophys Acta       Date:  2006-06-07

3.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-16       Impact factor: 17.586

Review 4.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

5.  Duchenne muscular dystrophy: life prolongation by noninvasive ventilatory support.

Authors:  Marcello Villanova; Beatrice Brancalion; Anokhi D Mehta
Journal:  Am J Phys Med Rehabil       Date:  2014-07       Impact factor: 2.159

6.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

Review 7.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David Gloss; Richard T Moxley; Stephen Ashwal; Maryam Oskoui
Journal:  Neurology       Date:  2016-02-02       Impact factor: 9.910

Review 8.  The importance of genetic diagnosis for Duchenne muscular dystrophy.

Authors:  Annemieke Aartsma-Rus; Ieke B Ginjaar; Kate Bushby
Journal:  J Med Genet       Date:  2016-01-11       Impact factor: 6.318

9.  Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.

Authors:  Thomas Voit; Haluk Topaloglu; Volker Straub; Francesco Muntoni; Nicolas Deconinck; Giles Campion; Sjef J De Kimpe; Michelle Eagle; Michela Guglieri; Steve Hood; Lia Liefaard; Afrodite Lourbakos; Allison Morgan; Joanna Nakielny; Naashika Quarcoo; Valeria Ricotti; Katie Rolfe; Laurent Servais; Claire Wardell; Rosamund Wilson; Padraig Wright; John E Kraus
Journal:  Lancet Neurol       Date:  2014-09-07       Impact factor: 44.182

10.  Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.

Authors:  Giulio Cossu; Stefano C Previtali; Sara Napolitano; Maria Pia Cicalese; Francesco Saverio Tedesco; Francesca Nicastro; Maddalena Noviello; Urmas Roostalu; Maria Grazia Natali Sora; Marina Scarlato; Maurizio De Pellegrin; Claudia Godi; Serena Giuliani; Francesca Ciotti; Rossana Tonlorenzi; Isabella Lorenzetti; Cristina Rivellini; Sara Benedetti; Roberto Gatti; Sarah Marktel; Benedetta Mazzi; Andrea Tettamanti; Martina Ragazzi; Maria Adele Imro; Giuseppina Marano; Alessandro Ambrosi; Rossana Fiori; Maria Pia Sormani; Chiara Bonini; Massimo Venturini; Letterio S Politi; Yvan Torrente; Fabio Ciceri
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

View more
  12 in total

Review 1.  Neuroprotection through G-CSF: recent advances and future viewpoints.

Authors:  Vikrant Rahi; Sumit Jamwal; Puneet Kumar
Journal:  Pharmacol Rep       Date:  2021-01-02       Impact factor: 3.024

Review 2.  Muscle cell-derived cytokines in skeletal muscle regeneration.

Authors:  Rachel J Waldemer-Streyer; Dongwook Kim; Jie Chen
Journal:  FEBS J       Date:  2022-01-24       Impact factor: 5.622

3.  Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.

Authors:  Angela Lek; Yuanfan Zhang; Keryn G Woodman; Shushu Huang; Alec M DeSimone; Justin Cohen; Vincent Ho; James Conner; Lillian Mead; Andrew Kodani; Anna Pakula; Neville Sanjana; Oliver D King; Peter L Jones; Kathryn R Wagner; Monkol Lek; Louis M Kunkel
Journal:  Sci Transl Med       Date:  2020-03-25       Impact factor: 17.956

4.  In vivo cerebellar circuit function is disrupted in an mdx mouse model of Duchenne muscular dystrophy.

Authors:  Trace L Stay; Lauren N Miterko; Marife Arancillo; Tao Lin; Roy V Sillitoe
Journal:  Dis Model Mech       Date:  2019-12-09       Impact factor: 5.758

5.  TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy.

Authors:  Dengqiu Xu; Sijia Li; Lu Wang; Jingwei Jiang; Lei Zhao; Xiaofei Huang; Zeren Sun; Chunjie Li; Lixin Sun; Xihua Li; Zhenzhou Jiang; Luyong Zhang
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-11-25       Impact factor: 12.910

6.  Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset.

Authors:  Virginie Mournetas; Emmanuelle Massouridès; Jean-Baptiste Dupont; Etienne Kornobis; Hélène Polvèche; Margot Jarrige; Alan R L Dorval; Maxime R F Gosselin; Antigoni Manousopoulou; Spiros D Garbis; Dariusz C Górecki; Christian Pinset
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-02-14       Impact factor: 12.910

7.  Polymeric nanoparticles functionalized with muscle-homing peptides for targeted delivery of phosphatase and tensin homolog inhibitor to skeletal muscle.

Authors:  Di Huang; Feng Yue; Jiamin Qiu; Meng Deng; Shihuan Kuang
Journal:  Acta Biomater       Date:  2020-10-11       Impact factor: 8.947

8.  In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse.

Authors:  Leonela Amoasii; Hui Li; Yu Zhang; Yi-Li Min; Efrain Sanchez-Ortiz; John M Shelton; Chengzu Long; Alex A Mireault; Samadrita Bhattacharyya; John R McAnally; Rhonda Bassel-Duby; Eric N Olson
Journal:  Nat Commun       Date:  2019-10-04       Impact factor: 14.919

9.  The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice.

Authors:  Yasunari Matsuzaka; Jun Tanihata; Yoshiko Ooshima; Daisuke Yamada; Masayuki Sekiguchi; Shouta Miyatake; Yoshitsugu Aoki; Mika Terumitsu; Ryu Yashiro; Hirofumi Komaki; Akihiko Ishiyama; Yasushi Oya; Yukiko U Inoue; Takayoshi Inoue; Shin'ichi Takeda; Kazuo Hashido
Journal:  BMC Med       Date:  2020-11-19       Impact factor: 8.775

10.  A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy.

Authors:  Gist H Farr; Melanie Morris; Arianna Gomez; Thao Pham; Elisabeth Kilroy; Elizabeth U Parker; Shery Said; Clarissa Henry; Lisa Maves
Journal:  Skelet Muscle       Date:  2020-10-15       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.